Keynote Speaker Trevor M Jones CBE and his keynote address to Pharma Integrates 2013. Pharma Integrates is an event for senior management in the pharmaceutical industry created and run by Life Sciences Index.

1. PHARMA INTEGRATES
2103
London
November 26th-27th
Prof Trevor M Jones CBE.
PhD DSc. FRSC. FRSM. Hon FRCP. FBPharmacolS. FFPM.FKC

2. …we simply have to do better !!
The Imperatives for Success
•
•
•
•
Connectivity
Partnerships
Strategic Alliances
Convergence (Technologies)

3. Convergence
Technologies:
• biomedicine, engineering, materials science,
computing, robotics, telecommunications and
web services
Cross-sector:
• diagnostics, therapeutics, devices, mobile
(m)health, social media, new data mining
services

4. Integration/Partnerships
•
•
•
•
•
•
•
•
•
•
Out sourcing / “Off-shoring”
Discovery support
Clinical Development
Data Handling
Regulatory
Pharmacovigilance
Manufacture
IT
Sales
Travel/Meetings/Events
………….etc
Connectivity
Partnership
Strategic Alliances

5.
Change is not a choice !!

6. Partnerships
“If you want to travel fast… go alone
If you want to travel far … go together”
Anon:African proverb

7. • Pfizer Splits Up Operations Ahead of Possible
Breakup
• More than splitting pills: Health care giant Abbott
Laboratories ready to spin off AbbVie
• New Novartis Chairman Initiates Strategic
Review.

8.
• AstraZeneca to axe 1,600 jobs in overhaul of drug R&D
• Teva to reduce workforce by 5000
• Merck to cut 8500 MORE jobs by 2015 (in addition to
the 7500 jobs cut from 2011 to 2012
• Valeant Pharmaceuticals International Inc said it would
cut 10 to 15 percent jobs after buying contact lens maker
Bausch & Lomb. Bausch and Lomb employs about
11,000 people worldwide

9. October 2013
Novartis to cut more than 440 jobs
in Britain
Shire restructuring will lead to loss
of 180 jobs in UK

10.
Eighteen GSK China staff held as
whistleblower allegations emerge
China Investigates Sanofi on Bribery
Accusations
Novartis faces Chinese bribery allegations
AUGUST 16, 2013

11. Main Challenges for the industry ?
Scientific
• MANY new (unvalidated) targets .Increasingly different
(and difficult) product types (Bio/nano/stratified RxDx)
• New R&D Models… SME/BigPharma alliances … “learn”&
“confirm”
Regulatory
• Continuing regulatory burden and bureaucracy ….. not just
“Q.S.E”………… but, importantly, also “HTA” needs
Business
• New Markets ...particularly BRIC +
• Company restructuring ..M&A ………………..and “cuts”
Economic
• Continuing “gloomy” Economic Climate

12. New “Biologicals”
New “Biologicals”
Cell Therapy
Permanent Replacement
Cell Therapy
Tissue Engineering
Permanent Replacement
Transient Cell Therapy
Tissue Engineering
Immunomodulation cell therapy
Transient Cell Therapy
Cosmoses / bioaesthetics
Immunomodulation cell therapy
Delivery vehicles
Cosmoses / bioaesthetics
Cell cancer vaccines
Delivery vehicles
Xenografts
Cell cancer vaccines
Regenerative Medicine
Xenografts
Regenerative Compounds.
Regenerative Medicine
Regenerative Scaffolds
Regenerative Compounds.
Regenerative Scaffolds
……….and new Drug Delivery Systems
……….and new Drug Delivery Systems

13.
…so much more to come !!!
Many “new” approaches to therapy
…are you prepared???

14. The imperative to change the Strategic Agenda
• Change Focus
• Growth areas ..speciality, emerging
markets, generics
• Fewer areas ,more external ,new
• Narrow R&D
R&D models
• Reduce sales force, new techniques,
• Rethink “S&M”
shift customer focus
• Reduce fixed infrastructure
• Increase Flexibility
• Outsource
• “Smart” Procurement
Re-engineering